All News

mechanicshands.JPG

Calcineurin Inhibitors in Anti-Synthetase Dermatomyositis ILD

d Jack Cush, MD

A pilot treatment study of patients with anti-aminoacyl-tRNA synthetase antibody–positive polymyositis/dermatomyositis-associated interstitial lung disease (anti-ARS-PM/DM-ILD) shows therapy with glucocorticoids and calcineurin inhibitors (CNI) to be highly effective. 

Read Article
stem%20cell.research.jpg

Biomarkers Predict Thrombosis in Lupus

d RheumNow

A composite risk score that included three biomarkers predicted thrombotic events among patients with systemic lupus erythematosus (SLE), a cross-sectional study found.

Read Article
healthcare.costs_.jpg

Drug Pricing Regulations in US and Canada

d Jack Cush, MD

Reuters reports on regulatory efforts by Canada and the US to curb the rising cost of drugs, especially expensive new medicines. 

Read Article
acupuncture.jpg

Pilot Study Targets Insulin Resistence in Fibromyalgia

d Jack Cush, MD

An unusual pilot study has shown that insulin resistence (IR), assessed by Hgb-A1c levels, was more prevalent in fibromyalgia (FM) patients compared to non-diabetic controls and that when FM patients were given metformin, half had complete resolution of their pain.

Read Article
cells.vessel.traffic.wbc_.jpg

Monocyte Patrolling Contributes to Lupus Glomerulonephritis

d Jack Cush, MD

Systemic lupus erythematosus (SLE) is an autoimmune disease with a propensity to develop glomerulonephritis (47-70%) or end-stage kidney disease despite therapy.

Read Article
Analysis of claims data compared hospitalized infection rates among 11,248 matched pairs of new initiators of abatacept or TNF inhibitors. Serious hosp infections were significantly lower in ABA vs infliximab (HR 0.63; 0.47-0.85), but similar to ETN & ADA https://t.co/JhXlC7p1A7

Links:

Dr. John Cush RheumNow ( View Tweet)

23 pts with Fibromyalgia were compared to non-diabetic Framingham and NHANES cohorts and shown to have significantly higher Hgb-A1c levels; suggesting insulin resistence in FM. 16 pts were given metformin and 50% had complete pain resolution (=0) https://t.co/OsbGFhcaCd

Links:

Dr. John Cush RheumNow ( View Tweet)

Fascinating case series - which suggests potential reasons to include a PSCK9 inhibitor in a statin-associated necrotizing myopathy — due to these meds possibly lowering HMGCR levels. https://t.co/Jblf2EDNmp

Links:

Paul Sufka, MD psufka ( View Tweet)

Time To Stop Labeling Physicians As Providers - thoughtful discussion of an unfortunate trend. https://t.co/W5c0sLHKal

Links:

Eric Ruderman JointMD ( View Tweet)

Biologic Survival study from Japan- ANSWER study w/ 4466 courses in 2494 pts (2009-17). Efficacy Survival best for ABA, TCZ; worst for IFX & CZP. Toxicity Dropouts most in IFX & ADA, least ABA & CZP. Remission best w/ ETN & ABA, least w/ GLM, IFX. https://t.co/IgRDKLemjW

Links:

Dr. John Cush RheumNow ( View Tweet)

"Everyone Needs A Coach" my TED-like talk from RheumNow Live 2019. https://t.co/G4jengfX0X

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA has approved Ruzurgi (amifampridine) for Lambert-Eaton myasthenic syndrome in children 6-17 years. Drug works by blocking potassium channel efflux in nerve terminals, opening Ca2+ channels & increasing acetylcholine release https://t.co/y7JFr76PTr

Links:

Dr. John Cush RheumNow ( View Tweet)

Long term safety of Secukinumab in PsO, PsA, & AS RCTs ( 96,054 patient-years) - favorable results with low incidence of serious infx (1.4, 1.9, 1.2, /100PYs), Candida (2.2, 1.5, 0.7/100pYs), IBD (0.01, 0.05, and 0.1/100PYs) or MACE (0.3, 0.4, 0.6). No TB. https://t.co/BTbBlOYj8W

Links:

Dr. John Cush RheumNow ( View Tweet)

In mice infected with the ZIKA virus, use of IL-1 receptor antagonist therapy mitigates placental dysfunction and perinatal injury by inhibiting microglial activation in the perinatal brain and by direct effects on the placenta. https://t.co/pgcOBoXMux

Links:

Dr. John Cush RheumNow ( View Tweet)

Danish population study of 55,037 found 210 men (37.6% RF+) & 456 women (41% RF+) RA pts; In women, body fat%, waist size, & obesity was assoc. w/ higher risk of RA. (10% higher for each 5% body fat, 5% for each 5- cm in waist, & 50% higher for obese) https://t.co/PRUBWcWXjC

Links:

Dr. John Cush RheumNow ( View Tweet)

Claims comparison of venous thromboembolic events (VTE) in treated RA pts finds a nonsignificant, but numerically higher rate of VTE in TOFA vs TNFi pts (0.60/100PY vs 0.34/100PY) (1.12/100PY vs 0.92/100PY), respectively. HR 1.33 (95% CI 0.78–2.24). https://t.co/JygSou07B1

Links:

Dr. John Cush RheumNow ( View Tweet)

A bit of welcome data on this -> Abatacept concentrations in maternal serum and breast milk during breastfeeding and an infant safety assessment https://t.co/TypfZZgcdK

Links:

Dr Philip Robinson philipcrobinson ( View Tweet)

New data on tocilizumab in pregnancy, upshot is: "Tocilizumab concentrations in cord blood and infant serum were 80–90% of those in maternal serum" https://t.co/qV7758L4Pm

Links:

Dr Philip Robinson philipcrobinson ( View Tweet)

In first-degree relatives of RA patients, comparing ACPA pos and neg FDR finds all moderate to severe periodontitis was significantly more prevalent in ACPA+ FDR (91%) compared to ACPA neg FDR (40%). From the Journal of Clinical Periodontology https://t.co/5d4YKGszZO

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up – DESIREABLE Results (5.3.19) WATCH it here https://t.co/uyYKxw21Kd or listen to the PODCAST on iTunes (Apple Car Play) or SoundCloud here>> https://t.co/HW0aDJo90Q

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×